TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02904226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTX-2011
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTX-2011
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTX-2011
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTX-2011
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTX-2011
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTX-2011
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTX-2011
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTX-2011
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days
Study: NCT05592197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib will be initially provided to patients first (dose: 8 mg qd for patients \< 60 kg, and 12 mg qd for patients ≥ 60 kg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenvatinib
Description: Lenvatinib will be initially provided to patients first (dose: 8 mg qd for patients \< 60 kg, and 12 mg qd for patients ≥ 60 kg)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: TACE will be performed one day after oral administration of lenvatinib. Either cTACE or DEB-TACE can be used, depending on the condition of each center.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: TACE will be performed one day after oral administration of lenvatinib. Either cTACE or DEB-TACE can be used, depending on the condition of each center.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiation (RT)
Description: RT will be given within 4 weeks after the first TACE with linear accelerator-based photon beams. Gross tumor volume is defined as intrahepatic tumor and vascular invasion including a 1-cm margin into the contiguous HCC. Prescription dose will be 4500-6000 cGy in 25 fractions.
Study: NCT04069221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iv infusion of [14C]-OZ439
Description: 15-minute 10-mL iv infusion of 100 μg \[14C\]-OZ439
Study: NCT00650494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir Hydrochloride Tablets 1000mg
Description: 1000mg, single dose fed
Study: NCT02904226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Specified dose on specified days
Study: NCT02104739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Single subcutaneous injection (10 mcg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Single dose orally (5 mg)
Study: NCT00650494

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valtrex® 1000 mg
Description: 1000mg, single dose fed
Study: NCT02904226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Specified dose on specified days
Study: NCT04611412

Intervention type: OTHER
Intervention: Risk Factors
Description: BMI in children and adolescents was compared with percentile charts developed by who for children from 5 to 19 years of age (WHO Growth Reference, 2007). Body mass index was defined as the ratio of body weight (in kg) to body length in the supine position or height in the standing position (m2).

Intervention type: OTHER
Intervention: Risk Factors
Description: BMI in children and adolescents was compared with percentile charts developed by who for children from 5 to 19 years of age (WHO Growth Reference, 2007). Body mass index was defined as the ratio of body weight (in kg) to body length in the supine position or height in the standing position (m2).
Study: NCT00021255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Study: NCT02346448

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic sphincterotomy
Description: sphincterotomy during ERCP

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: balloon dilatation for 3 minutes
Description: balloon dilatation during ERCP using 10mm balloon

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: balloon dilatation for 6 minutes
Description: balloon dilatation during ERCP using 10mm balloon
Study: NCT03455946

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DASH cloud with Alexa
Description: Participants will download and install the Alexa and Nutritionix application (app) onto their smartphone and study staff will setup the study-specific account to send data to Duke's software system called Prompt. Participants will be instructed to invoke through voice their dietary intake daily for three months using the Nutritionix app through the Amazon Alexa personal assistant. DASH Cloud will access participant's dietary intake data through the Nutritionix application programing interface (API) for three months. Participants' data will automatically be uploaded from the Nutritionix app via the API that links the device with DASH Cloud. DASH Cloud will run an algorithm and send a daily or weekly feedback text message with a score reflecting DASH adherence for the prior days or week's food consumption using a previously validated scoring system.
Study: NCT02152969

Intervention type: DRUG
Group type: OTHER
Intervention: Telmisartan

Intervention type: DRUG
Group type: OTHER
Intervention: Telmisartan
Study: NCT00021255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Study: NCT02104739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Single dose orally (5 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Single dose orally (5 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Single dose orally (5 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Single dose orally (5 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Single dose orally (5 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Single dose orally (5 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Single dose orally (5 mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saxagliptin
Description: Single dose orally (5 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Single dose orally (5 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Single dose orally (5 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Single dose orally (5 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide extended-release (ER)
Description: Subcutaneous injection (2mg) weekly for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide extended-release (ER)
Description: Subcutaneous injection (2mg) weekly for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide extended-release (ER)
Description: Subcutaneous injection (2mg) weekly for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide extended-release (ER)
Description: Subcutaneous injection (2mg) weekly for 6 weeks
Study: NCT00021255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study: NCT02104739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide extended-release (ER)
Description: Subcutaneous injection (2mg) weekly for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide extended-release (ER)
Description: Subcutaneous injection (2mg) weekly for 6 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets and Placebo (normal saline) injections

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets and Placebo (normal saline) injections

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets and Placebo (normal saline) injections

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets and Placebo (normal saline) injections

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets and Placebo (normal saline) injections

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets and Placebo (normal saline) injections

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets and Placebo (normal saline) injections

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets and Placebo (normal saline) injections

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets and Placebo (normal saline) injections

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets and Placebo (normal saline) injections

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets and Placebo (normal saline) injections

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets and Placebo (normal saline) injections
Study: NCT03287635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticotropin 80Unit/Ml Repository Injection
Description: H.P. Acthar Gel (repository corticotropin injection) is an adrenocorticotropic hormone (ACTH) analogue used for: Treatment during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus.
Study: NCT03670836

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dilapan
Description: Dilapan-S® is a mechanical method for cervical ripening using rods made of a patented hydrogel Aquacryl, it is marketed in form of rods of 3 and 4 mm diameter. It is FDA approved for cervical ripening.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: 25mcg of Misoprostol will be administered orally every 2 hours (maximum of 6 doses)~Misoprostol is a prostaglandin E1 analog approved for treatment and prevention of gastric ulcers. The use of Misoprostol appears to be safe and effective for induction of labor when used in low dose.
Study: NCT00396032

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: For the initial treatment, 2 mL of placebo instilled into each lumen of the HD catheter; subsequent treatments were 2 mL of open-label tenecteplase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenecteplase
Description: For the initial treatment, 2 mL of reconstituted lyophilized tenecteplase instilled into each lumen of the HD catheter; subsequent treatments were 2 mL of open-label tenecteplase
Study: NCT01711372

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Groundskeeper game for controls
Description: The Groundskeeper game is a go/no go task that captures reaction time and movement using the accelerometers and touch capabilities of the Sifteo cubes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Groundskeeper game for ADHD
Description: The Groundskeeper game is a go/no go task that captures reaction time and movement using the accelerometers and touch capabilities of the Sifteo cubes.
Study: NCT03789617

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EBViNT Cell
Description: 1. Dosage: 1 bag containing 1.4x10\^9 cells/100mL~2. Administration: Inject intravenously over 30 minutes~3. Dosing schedule: Single dose
Study: NCT00611910

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sirolimus-eluting stent
Description: due to randomization Cypher stent will be implanted

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: paclitaxel-eluting stent
Description: due to randomization Taxus stent will be implanted

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: biodegradable-polymer-based sirolimus-eluting stent
Description: due to randomization a rapamycin-eluting stent with biodegradable polymer will be implanted

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: bare metal stents
Description: Due to randomization one bare-metal stent will be implanted. The decision about the stent type will be up to the interventionalist
Study: NCT02749526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar
Description: 30mg civ24h d0-6.A course of 3 weeks, after two course of chemotherapy the CT/MR/ultrasonic gastroscopy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposo
Description: 135mg/m2 D1.A course of 3 weeks, after two course of chemotherapy the CT/MR/ultrasonic gastroscopy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 25mg/m2 D1-3.A course of 3 weeks, after two course of chemotherapy the CT/MR/ultrasonic gastroscopy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gimeracil and Oteracil Potassium （Tegafur）
Description: 40mg bid，D1-14.A course of 3 weeks, after two course of chemotherapy the CT/MR/ultrasonic gastroscopy.
Study: NCT01188174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: The present protocol aims to test the strategy of an early Reduced Intensity Conditioning (RIC) allo-SCT; in combination with a sequential preparative regimen for allo-SCT (Clofarabine, Intermediate dose Ara-C chemotherapy, followed by RIC with Cyclophosphamide, IV Busulfan and ATG; and delayed prophylactic infusion of donor lymphocytes (DLI) will be able to improve the outcome of patients with primary treatment failure AML.
Study: NCT00671359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-701 600mg
Description: TR-701 600mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-701 600mg
Description: TR-701 600mg
Study: NCT03566069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Oxytocin
Description: 32IU (16IU\*2) of OT, Sorbitol, Benzyl, alcohol glycerol, distilled water.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal Placebo
Description: 32IU (16IU\*2) of Sorbitol, Benzyl, alcohol glycerol.
Study: NCT02162641

Intervention type: PROCEDURE
Intervention: Sentinel lymph node biopsy
Study: NCT00677703

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily Text Messages
Description: Text message reminders to take oral contraception daily:~Each text message will be a short educational message listing the benefits of contraceptive use and providing instructions for avoiding common medication errors.
Study: NCT03388775

Intervention type: OTHER
Intervention: deep venous thrombosis
Description: Five-year prospective analysis of deep venous thrombosis performed by the RHEUNI group of five public schools in the State of São Paulo.
Study: NCT02152969

Intervention type: DRUG
Group type: OTHER
Intervention: Amlodipine

Intervention type: DRUG
Group type: OTHER
Intervention: Amlodipine

Intervention type: DRUG
Group type: OTHER
Intervention: Chlorthalidone

Intervention type: DRUG
Group type: OTHER
Intervention: Chlorthalidone
Study: NCT00278525

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard of care
Description: standard of care medication will be given

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stem cell transplantation
Description: The following is intervention: stem cell transplantation after conditioning regimen
Study: NCT02569034

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Magnetic Resonance Imaging
Description: Both groups will have the fMRI performed once. The fMRI will be use to to dissociate activity associated with both reward wanting and reward liking using the EEfRT. Learning more about the brain basis of components of anhedonia in both young and older adults is important in the context of previous research showing that risk-taking behavior and reward sensitivity changes with age, enhancing the knowledge of anhedonia.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Functional Magnetic Resonance Imaging
Description: Both groups will have the fMRI performed once. The fMRI will be use to to dissociate activity associated with both reward wanting and reward liking using the EEfRT. Learning more about the brain basis of components of anhedonia in both young and older adults is important in the context of previous research showing that risk-taking behavior and reward sensitivity changes with age, enhancing the knowledge of anhedonia.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Effort-Expenditure for Rewards Task
Description: Both groups with have the EEfRT performed once. The EEfRT is an effort-based decision-making task that measures reward wanting, in contrast to commonly used anhedonia questionnaires, which focus on reward liking. This novel task may provide a useful measure of components of anhedonia in older adults and in different patient populations.
Study: NCT03465163

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: The device is called the Medtronic Activa PC+S system. Two devices will be implanted per participant. The electrodes will be surgically implanted bilaterally into the hippocampus and anterior nucleus of the thalamus.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: The device is called the Medtronic Activa PC+S system. Two devices will be implanted per participant. The electrodes will be surgically implanted bilaterally into the hippocampus and anterior nucleus of the thalamus.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: The device is called the Medtronic Activa PC+S system. Two devices will be implanted per participant. The electrodes will be surgically implanted bilaterally into the hippocampus and anterior nucleus of the thalamus.
Study: NCT02569034

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Effort-Expenditure for Rewards Task
Description: Both groups with have the EEfRT performed once. The EEfRT is an effort-based decision-making task that measures reward wanting, in contrast to commonly used anhedonia questionnaires, which focus on reward liking. This novel task may provide a useful measure of components of anhedonia in older adults and in different patient populations.
Study: NCT05182736

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TRAIL intervention
Description: The TRAIL program is comprised of a multi-tier system of strategies: Universal strategies impact the entire school via a school-wide social norms marketing campaign and school-climate change activities. School staff trainings and professional development activities focus on enhancing protective factors for students to reduce the effects of stressful life events and trauma, improving classroom management, linking students to resources, and improving the overall school climate for students and staff. Targeted strategies include an in-school curriculum and service learning component, which impact all ninth grade students at the intervention high schools and all eighth grade students at the intervention middle schools. Intensive strategies are intended for a subset of youth and their caregivers with identified increased risk-factors, and they include peer mentoring, after-school running/positive youth development programming, summer programming, and parent workshop support.
Study: NCT00030576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Study: NCT00573066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dosage levels: Dose Level 1: Loading dose 0.35mcg/kg and CIVI 0.25mcg/kg/hr Dose Level 2: Loading Dose of 0.7mcg/kg and CIVI 0.5mcg/kg/hr and Dose Level 3: Loading Dose 1 mcg/kg and CIVI 0.75 mcg/kg/hr.
Study: NCT02489461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VM-1500
Description: VM-1500 up to 96 weeks
Study: NCT03771872

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Prism Adaptation Therapy
Description: Hand trajectory will deviate to the right side in the virtual reality.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Therapy
Description: The therapy is the same as the real virtual prism adaptation therapy, but there will be no deviation of the hand trajectory in the virtual reality.
Study: NCT00838487

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: condroflex and exercise
Description: 1 sachet oral once a day by 12 Weeks / therapeutic exercise 3 times a week
Study: NCT01369173

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mexican or American foods
Description: Participants will be randomized to an isocaloric Indigenous Mexican or a Western diet for 24 days. All foods and beverages will be prepared by the Human Nutrition Laboratory at the Fred Hutchinson Cancer Research Center. After a 4-week wash-out period, participants will cross over to the other arm and be given the alternate diet for 24 days. Blood and urine specimens will be collected before and after each feeding period to test baseline and post-intervention metabolic response as defined by various inflammatory and cancer susceptibility biomarkers including insulin-like growth factor 1 (IGF1), insulin-like growth factor binding protein 3 (IGFBP3), leptin, adiponectin, interleukin-6 (IL-6), C-reactive protein (CRP) and SAA (serum amyloid-A). DNA extracted from whole blood will be used to test whether a panel of 128 Ancestry Informative Markers (AIMs) is associated with metabolic response to the diets and other phenotypic traits of obesity, which relate to breast cancer risk.
Study: NCT00838487

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill and exercise
Description: 1 sachet oral once a day by 12 Weeks / therapeutic exercise 3 times a week